Recently, FAS ligands, one of the key components in cancer cell immunity, showed more immunoreactivity in WD-pNETs, a negative correlation with Ki-67, and lower expression in patients presumed to have a poorer prognosis [83]. This evidence concerns the gene MKI67 and Wilson disease.